Ignite Creation Date:
2025-12-24 @ 1:59 PM
Ignite Modification Date:
2026-01-11 @ 6:31 PM
Study NCT ID:
NCT06280495
Status:
RECRUITING
Last Update Posted:
2025-05-30
First Post:
2024-02-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sponsor:
Sun Yat-sen University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
INTENSIFY-CRC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None